Language Selection

Get healthy now with MedBeds!
Click here to book your session

Protect your whole family with Orgo-Life® Quantum MedBed Energy Technology® devices.

Advertising by Adpathway

         

 Advertising by Adpathway

Dual Therapy Reduces Brain Membrane Thickening in Infant With Rare Nevus Syndrome

2 hours ago 13

PROTECT YOUR DNA WITH QUANTUM TECHNOLOGY

Orgo-Life the new way to the future

  Advertising by Adpathway

A targeted experimental drug combination consisting of the nucleoside analogue azacitidine and the MEK inhibitor trametinib successfully produced a rapid reduction of diffuse leptomeningeal thickening in a young infant diagnosed with congenital melanocytic nevus syndrome and symptomatic neurocutaneous melanosis. The patient, who initially presented with severe clinical complications related to massively raised intracranial pressure during early infancy, demonstrated sustained radiological and developmental stability through 53 months of age under continued targeted care.

Congenital melanocytic nevus syndrome is a rare mosaic RASopathy that predominantly arises from postzygotic, mosaic activating mutations in codon 61 of the NRAS proto-oncogene in up to 80 percent of documented cases. These developmental genetic variants originate in early ectodermal precursor cells, resulting in extensive melanocyte deposits across the skin and, in approximately 20 to 30 percent of patients, within the central nervous system parenchyma and leptomeningeal membranes. Crucially, melanocytic lesions within the leptomeninges carry a grim clinical prognosis due to a high likelihood of malignant transformation into pediatric melanomas, which have historically been considered universally fatal once neurological symptoms emerge.

The infant reported in the study was born at term with giant, light brown melanocytic nevi displaying multiple dark brown nodular regions across the neck, upper thorax, and arms, alongside multiple satellite nevi covering approximately 20 percent of his total body surface area. At four weeks of life, the infant developed recurrent episodes of oxygen desaturation and apnea that were subsequently determined to stem from critically elevated intracranial pressure. Clinical teams immediately placed a ventriculoperitoneal shunt to relieve intracranial pressure, while repeated cerebrospinal fluid cytology confirmed the absence of identifiable malignant melanoma cells despite a clinically assessed transformation risk exceeding 50 percent.

Comprehensive molecular profiling supported the clinical diagnosis and illuminated the underlying genetic drivers behind the infant’s pathology. Next-generation sequencing performed on genomic DNA extracted from a biopsy of a cutaneous melanocytic lesion identified the classic activating p.Gln61Lys pathogenic variant in exon 3 of the NRAS gene with an allele frequency of 35 percent. Parallel testing on germline DNA from peripheral blood samples was negative for the somatic NRAS mutation, confirming its postzygotic mosaic distribution. However, germline sequencing did uncover an inherited heterozygous variant, p.Glu318Lys, in the MITF1 gene with an allele frequency of 50 percent, inherited through the maternal lineage. While this specific MITF1 alteration represents a recognized predisposing factor in familial melanoma and renal cell carcinoma, its precise mechanistic interaction with mosaic neurocutaneous melanosis remains under scientific investigation.

Faced with extensive, life-threatening leptomeningeal involvement and high transformation risks, the clinical team designed an individualized pharmacological regimen pairing azacitidine with trametinib, initiating treatment on the infant’s 47th day of life. The rationale was directly informed by prior preclinical investigations and clinical observations from an older pediatric patient with advanced CNS melanoma, where the combination prolonged disease control and demonstrated synergistic activity capable of delaying secondary resistance against MEK inhibition in NRAS-mutated cells. Azacitidine was administered subcutaneously at 75 milligrams per square meter daily for seven consecutive days across 28-day treatment cycles, while trametinib was administered continuously as an oral formulation at a dosage of 0.035 milligrams per kilogram once daily.

Follow-up magnetic resonance imaging demonstrated a dramatic and rapid regression of extensive leptomeningeal thickening and parenchymatous lesions in the brain and spinal cord within months of initiating dual therapy. Neuroaxis imaging obtained at four months of age revealed marked regression of cerebellar and pontine lesions as well as intraspinal meningeal enhancement, leaving only minimal residual focal abnormalities along the spinal cord.

The patient tolerated the dual-agent regimen over an extended treatment course, experiencing manageable side effects that included an intermittent eczematous skin rash, transient deceleration of longitudinal linear growth, and periodic nausea and vomiting. After receiving 18 full cycles of azacitidine, clinicians elected to discontinue the injectable nucleoside analogue to eliminate injection discomfort and treatment-associated emesis, given that the infant’s leptomeningeal disease had stabilized into minimal residual tissue. The child was maintained on single-agent daily oral trametinib.

Throughout the multi-year follow-up period, the child achieved normal neurological and physical developmental milestones, tracking at the 69th percentile for height and the 89th percentile for weight at 45 months. The child’s clinical course was nevertheless marked by mechanical and infectious shunt complications, including an episode of Streptococcus pneumoniae meningitis and recurring ventriculoperitoneal shunt malfunctions that produced transient intracranial hypertension and papilledema, all of which successfully resolved with surgical revisions, confirming an ongoing necessity for long-term cerebrospinal fluid diversion.

The biological mechanisms underlying the combination’s therapeutic efficacy likely involve distinct epigenetic and signaling vulnerabilities characteristic of congenital melanocytic lesions. Unlike adult cutaneous melanomas that frequently harbor UV-induced TERT promoter point mutations, melanomas arising in congenital nevus syndrome exhibit marked CpG hypermethylation within the TERT promoter region, driving aberrant telomerase reactivation and cellular immortalization. By inhibiting DNA methyltransferases, azacitidine is hypothesized to reverse or suppress this pathogenic promoter hypermethylation, while trametinib simultaneously blocks downstream hyperactive MAPK signaling driven by the mosaic NRAS mutation. This coordinated molecular blockade appears capable of arresting the clonal expansion of nevus-associated cells within the leptomeningeal compartment before terminal malignant transformation occurs.

Despite the remarkable clinical outcome observed in this patient, the investigators emphasized several critical caveats and limitations inherent to single-patient case studies. Furthermore, while the child remains free of melanoma and clinically healthy at 53 months of age, lifelong malignant susceptibility persists in congenital melanocytic nevus syndrome, leaving the optimal duration of ongoing trametinib maintenance and potential late toxicities from early antineoplastic exposures uncertain.

The clinical decision to initiate this experimental combination therapy was grounded in prior observations from a separate pediatric case involving advanced central nervous system melanoma. In that earlier instance, a 32-month-old boy demonstrated a measurable clinical and radiological response to the same azacitidine and trametinib regimen. Although that patient ultimately succumbed to rapidly progressive disease after five months of treatment, the duration of response appeared longer than what has been documented for trametinib monotherapy. These clinical observations were further supported by in vitro studies using NRAS-mutated melanoma cells, which indicated that combined exposure to the two agents postponed the development of trametinib resistance. The data also suggested synergistic effects against cells that had already developed resistance to trametinib alone, providing a mechanistic rationale for applying the combination to the current infant patient.

The molecular landscape of melanomas arising in congenital melanocytic nevus syndrome differs significantly from that of conventional pediatric or adult melanomas. While typical melanomas often exhibit UV-induced mutational spectra, including alterations in the PTEN tumor suppressor gene and activating mutations in the TERT promoter, CMNS-associated melanomas generally lack these specific genetic changes. Instead, these tumors display high levels of CpG hypermethylation in the TERT promoter region, a finding that correlates with elevated TERT expression. This distinct epigenetic profile suggests an alternative mechanism for telomerase reactivation. The authors hypothesize that the efficacy of azacitidine in this case may stem from its ability to inhibit DNA methyltransferases, thereby potentially reducing or preventing this specific promoter hypermethylation and interrupting the clonal evolution of nevus-associated cells.

The patient’s genetic profile included a heterozygous germline variant in the MITF1 gene, inherited through the maternal line. This specific p.Glu318Lys alteration is recognized as a pathogenic variant associated with familial melanoma and renal cell carcinoma in other populations. Given that the patient’s maternal grandfather was diagnosed with malignant melanoma at age 40, the presence of this MITF1 variant may represent an additional risk factor for melanoma development in this individual. However, the precise role of MITF1 germline variants in the pathogenesis of neurocutaneous melanosis remains unclear. The authors note that while hypermethylation of MITF1 plays a role in melanoma development, the interaction between this germline mutation and the mosaic NRAS variants in the context of congenital melanocytic nevus syndrome is not fully understood.

Long-term management of the patient is complicated by the necessity of permanent cerebrospinal fluid diversion. The hydrocephalus observed in this case is likely secondary to impaired CSF resorption caused by the underlying leptomeningeal disease. The patient has experienced multiple shunt complications, including an episode of Streptococcus pneumoniae meningitis and recurrent shunt dysfunctions. These mechanical failures have resulted in symptoms of increased intracranial pressure, such as bilateral papilledema, which have resolved following surgical revisions. The clinical team anticipates that the patient will require the ventriculoperitoneal shunt permanently. Additionally, the long-term prognosis regarding potential sequelae from early exposure to azacitidine and trametinib remains uncertain, and no endpoint for the ongoing trametinib treatment has been established.

Subject of Research: Targeted drug therapy for neurocutaneous melanosis in congenital melanocytic nevus syndrome

Article Title: Efficacy of azacitidine and trametinib against leptomeningeal melanosis associated with congenital melanocytic nevus syndrome

Article References: Raljević, L., Komlosi, K., Feige, U., Eckenweiler, M., Lassmann, S., Jrad, H. B. H., Werner, M., Fischer, J., Has, C., Feuchtinger, T., Uhl, M., Niemeyer, C. M., & Hettmer, S. (2026). Efficacy of azacitidine and trametinib against leptomeningeal melanosis associated with congenital melanocytic nevus syndrome. Molecular and Cellular Pediatrics, 13(1), Article 18. https://doi.org/10.1186/s40348-026-00233-4

Image Credits: AI Generated

DOI: 10.1186/s40348-026-00233-4

Keywords: Congenital melanocytic nevus syndrome, Leptomeningeal melanosis, Neurocutaneous melanosis, Azacitidine, Trametinib, NRAS mutation, MITF1 gene, Pediatric oncology, Targeted therapy, Central nervous system, MAPK pathway, Intracranial pressure, Hydrocephalus, Ventriculoperitoneal shunt, Magnetic resonance imaging, Melanoma risk, Case report

Read Entire Article

         

        

Start the new Vibrations with a Medbed Franchise today!  

Protect your whole family with Quantum Orgo-Life® devices

  Advertising by Adpathway